Evidence map›Paper›PMID 23974608›Full record

ArticleBone marrow transplantation2014

Reovirus as a successful ex vivo purging modality for multiple myeloma.

C M Thirukkumaran, Z Q Shi, J Luider, K Kopciuk, N Bahlis, P Neri, M Pho, D Stewart, A Mansoor, D G Morris

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. OncolyticTurkish journal of haematology : official journal of Turkish Society of Haematology · 2024
    Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Gene and virotherapy for hematological malignancies.International journal of hematology · 2016
    Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

C M Thirukkumaran1] Department of Oncology, University of Calgary, Calgary, Alberta, Canada [2] Department of Oncology, Tom Baker Cancer Center, Calgary, Alberta, Canada.
Z Q ShiDepartment of Oncology, Tom Baker Cancer Center, Calgary, Alberta, Canada.
J LuiderCalgary Laboratory Services, Calgary, Alberta, Canada.
K Kopciuk1] Department of Oncology, University of Calgary, Calgary, Alberta, Canada [2] Department of Oncology, Tom Baker Cancer Center, Calgary, Alberta, Canada.
N Bahlis1] Department of Oncology, University of Calgary, Calgary, Alberta, Canada [2] Department of Oncology, Tom Baker Cancer Center, Calgary, Alberta, Canada.
P Neri1] Department of Oncology, University of Calgary, Calgary, Alberta, Canada [2] Department of Oncology, Tom Baker Cancer Center, Calgary, Alberta, Canada.
M PhoDepartment of Public Health Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
D Stewart1] Department of Oncology, University of Calgary, Calgary, Alberta, Canada [2] Department of Oncology, Tom Baker Cancer Center, Calgary, Alberta, Canada.
A MansoorCalgary Laboratory Services, Calgary, Alberta, Canada.
D G Morris1] Department of Oncology, University of Calgary, Calgary, Alberta, Canada [2] Department of Oncology, Tom Baker Cancer Center, Calgary, Alberta, Canada.
University of Calgary · CACalgary Laboratory Services · CAUniversity of British Columbia · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autologous stem cell rescue (ASCT) following high-dose myeloablative chemotherapy is considered to be a therapeutic option for many multiple myeloma (MM) patients; however relapse post ASCT presents a major challenge. The oncolytic potential of reovirus has been previously demonstrated and is currently undergoing phase I monotherapy clinical trials for MM and phase II/III clinical trials for solid tumors. Here we tested the hypothesis that reovirus can successfully purge MM in a murine model that partially recapitulates human MM. RPMI 8226, MM1S, H929 and U266 human myeloma cell lines were exposed to reovirus and oncolysis was assessed. Apheresis product admixed with MM cells was purged with live reovirus (LV) or dead virus (DV) and purging efficacy was monitored via flow cytometry, reverse transcribed-PCR (RT-PCR) and disease relapse in non obese diabetic/severe combined immune deficient (NOD/SCID) mice. Significant LV purging was seen with MM1S, H929 and U266 and the complete ex vivo purging achieved with RPMI 8226 was confirmed by flow cytometry, RT-PCR and absence of disease relapse in vivo. Mice that received LV-purged autografts exhibited 100% survival in comparison to mice that received DV-purged controls. Reovirus's unique ability to kill MM while sparing hematopoietic stem cells places it as an attractive purging agent for MM during ASCT.

Indexed as

Oncolytic VirotherapyReoviridaeAnimalsBlood Component RemovalBone Marrow PurgingCell LineCell Line, TumorFlow CytometryGreen Fluorescent ProteinsHumansMaleMiceMice, Inbred NODMice, SCIDMultiple MyelomaRecurrenceGreen Fluorescent Proteins

Identifiers

PMID23974608
OpenAlexW2030339556

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.